These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial. Kornstein SG; Bose A; Li D; Saikali KG; Gandhi C J Clin Psychiatry; 2006 Nov; 67(11):1767-75. PubMed ID: 17196058 [TBL] [Abstract][Full Text] [Related]
4. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729 [TBL] [Abstract][Full Text] [Related]
5. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. Montgomery SA; Nil R; Dürr-Pal N; Loft H; Boulenger JP J Clin Psychiatry; 2005 Oct; 66(10):1270-8. PubMed ID: 16259540 [TBL] [Abstract][Full Text] [Related]
6. An open-label study of escitalopram in body dysmorphic disorder. Phillips KA Int Clin Psychopharmacol; 2006 May; 21(3):177-9. PubMed ID: 16528140 [TBL] [Abstract][Full Text] [Related]
7. Escitalopram in the treatment of impulsive-compulsive internet usage disorder: an open-label trial followed by a double-blind discontinuation phase. Dell'Osso B; Hadley S; Allen A; Baker B; Chaplin WF; Hollander E J Clin Psychiatry; 2008 Mar; 69(3):452-6. PubMed ID: 18312057 [TBL] [Abstract][Full Text] [Related]
8. Escitalopram prevents relapse in older patients with major depressive disorder. Gorwood P; Weiller E; Lemming O; Katona C Am J Geriatr Psychiatry; 2007 Jul; 15(7):581-93. PubMed ID: 17586783 [TBL] [Abstract][Full Text] [Related]
9. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. Robinson RG; Jorge RE; Moser DJ; Acion L; Solodkin A; Small SL; Fonzetti P; Hegel M; Arndt S JAMA; 2008 May; 299(20):2391-400. PubMed ID: 18505948 [TBL] [Abstract][Full Text] [Related]
10. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder. Bech P; Lönn SL; Overø KF J Clin Psychiatry; 2010 Feb; 71(2):121-9. PubMed ID: 19961809 [TBL] [Abstract][Full Text] [Related]
11. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Allgulander C; Florea I; Huusom AK Int J Neuropsychopharmacol; 2006 Oct; 9(5):495-505. PubMed ID: 16316482 [TBL] [Abstract][Full Text] [Related]
12. Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation. Grant JE; Potenza MN Int Clin Psychopharmacol; 2006 Jul; 21(4):203-9. PubMed ID: 16687991 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074 [TBL] [Abstract][Full Text] [Related]
14. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597 [TBL] [Abstract][Full Text] [Related]
15. Factors predicting relapse in elderly patients with major depressive disorder treated with escitalopram in an outpatient setting. Dolberg O; Larsson Lönn S; Kvist K Curr Med Res Opin; 2014 Jul; 30(7):1301-7. PubMed ID: 24628498 [TBL] [Abstract][Full Text] [Related]
16. Escitalopram versus placebo in the treatment of dysthymic disorder. Hellerstein DJ; Batchelder ST; Hyler S; Arnaout B; Toba C; Benga I; Gangure D Int Clin Psychopharmacol; 2010 May; 25(3):143-8. PubMed ID: 21811192 [TBL] [Abstract][Full Text] [Related]
17. Escitalopram treatment of kleptomania: an open-label trial followed by double-blind discontinuation. Koran LM; Aboujaoude EN; Gamel NN J Clin Psychiatry; 2007 Mar; 68(3):422-7. PubMed ID: 17388713 [TBL] [Abstract][Full Text] [Related]
18. Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder. François C; Montgomery SA; Despiegel N; Aballéa S; Roïz J; Auquier P Int J Clin Pract; 2008 Nov; 62(11):1693-702. PubMed ID: 18759783 [TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression. Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348 [TBL] [Abstract][Full Text] [Related]
20. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study. Brown ES; Howard C; Khan DA; Carmody TJ Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]